Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full...(expenses 11217 6002 ...),Health

Income from operations 8,588 3,656 17,924 8,898

Interest income 671 118 2,279 245

Interest expense (5) (72) (5) (231)

Other (loss) income (16) (1) 28 41

Income before income taxes 9,238 3,701 20,226 8,953

Income tax (benefit) expense (6,190) 114 (5,780) 274

Net income $15,428 $3,587 $26,006 $8,679

Net income per share: (1)(2)

Basic $0.93 $0.43 $1.59 $0.82

Diluted $0.87 $0.06 $1.48 $0.10

Shares used to compute net income per

share: (1)(2)

Basic 16,535 239 16,336 191

Diluted 17,754 1,674 17,616 1,635

(1) As a result of the conversion of the Company's preferred stock into

11,032 shares of common stock upon completion of the Company's initial

public offering in November 2007, there is a lack of comparability in

the basic and diluted net income per share amounts for the periods

presented above.

(2) For the three and nine months ended September 30, 2007, the Company

had net income of $3,587 and $8,679, respectively, of which $3,485 and

$8,522, respectively, was allocated to preferred stockholders for

purposes of calculating net income per share pursuant to the terms of

the preferred stock, resulting in $102 and $157, respectively, of net

income allocable to common stockholders.

GENOPTIX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par value
'/>"/>